APOG news

Apogee Enterprises extended the employment of CEO Donald Nolan for six months. The move ensures continued leadership and a smooth transition to a permanent CEO.

Second-quarter net sales increased to $391 1 million driving a raise in fiscal 2027 adjusted diluted EPS guidance to 3 00 3 40 due to strong execution and acquisitions including Kalwall and Groglass.

Apogee Enterprises announced the completion of its acquisition of SIA Groglass, a leader in anti-reflective coatings, to strengthen its Performance Surfaces portfolio. The deal expands the company's offerings in display, architectural, and technical applications.

Apogee Enterprises announces the election of Julie K. Streich to its board and Audit Committee, effective September 11, 2026. The appointment adds significant financial and governance experience to the leadership team.

Apogee Enterprises announced a definitive agreement to acquire Daugava Finance S.A., the Estonia-based investment management subsidiary of management group Tallink Grupp, for $34 million in cash. This strategic acquisition extends Apogee's footprint in the Nordic region and aligns with its growth go…

Apogee Enterprises announced the completion of its acquisition of Kalwall Companies from the Keller family for up to $115 million. This strategic transaction strengthens Apogee's market position by integrating differentiated daylighting capabilities and a strong architectural brand.

Apogee Enterprises reported a significant increase in earnings and gross margin for its first fiscal quarter of 2027. Management reaffirmed fiscal 2027 guidance while maintaining a disciplined approach to capital allocation.

AbbVie Inc. has entered into a definitive merger agreement to acquire Apogee Therapeutics, Inc. through a subsidiary merger structure. The transaction expands AbbVie's therapeutic pipeline and represents a significant M&A activity in the pharmaceutical sector.

Apogee Therapeutics signed an Antibody Discovery Agreement with Paragon Therapeutics effective June 17, 2026, for discovery and development of monospecific antibody candidates. The agreement includes a concurrent License Agreement enabling Apogee to further develop, manufacture and commercialize res…